ADVAIR HFA 230/21 Rx

Select the drug indication to add to your list

ADVAIR HFA 230/21

Asthma/COPD
Only 4 drugs may be compared at once

Generic Name and Formulations:

Fluticasone propionate 230mcg, salmeterol (as xinafoate) 21mcg; per inh; metered-dose inhaler; CFC-free.

Company:

GlaxoSmithKline

Select therapeutic use:

Indications for ADVAIR HFA 230/21:

Treatment of asthma in patients not adequately controlled on a long-term asthma control medication [eg, inhaled corticosteroid (ICS)] or whose disease warrants initiation of both an ICS and LABA.

Limitations Of use:

Not for relief of acute bronchospasm.

Adult:

Allow approx. 12hrs between doses. Initially 2 inh of 45/21 or 115/21 or 230/21 twice daily, based on disease severity and previous asthma therapy. If insufficient response after 2wks, use next higher strength. Max: 2 inh of 230/21 twice daily. Rinse mouth after use.

Children:

<12yrs: not established.

Contraindications:

Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures.

Warnings/Precautions:

Increased risk of asthma-related events (death, hospitalizations, intubations) with LABA monotherapy (without ICS). Do not initiate in rapidly or acutely deteriorating asthma. Not for use with other long-acting β2-agonists. Do not exceed recommended dose. Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Monitor for signs/symptoms of pneumonia. Immunosuppressed. Tuberculosis. Systemic infections. Ocular herpes simplex. If exposed to chickenpox or measles, consider immune globulin prophylaxis or antiviral ­treatment. Monitor for adrenal insufficiency when transferring from systemic steroids. May need supplemental systemic corticosteroids during periods of stress or a severe asthma attack. May unmask previously suppressed allergic conditions. Reevaluate periodically. Monitor for hypercorticism and HPA axis suppression (if occurs, discontinue gradually), growth in children, intraocular pressure, glaucoma, or cataracts. Discontinue if paradoxical bronchospasm occurs; use alternative therapy. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertension). Eosinophilic conditions. Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Hypokalemia. Hyperglycemia. Hepatic impairment; monitor. Assess bone mineral density if risk factors exist (eg, prolonged immobilization, osteoporosis, postmenopausal, advanced age, others). Labor & delivery. Pregnancy (Cat.C). Nursing mothers.

See Also:

ADVAIR HFA 45/21

ADVAIR HFA 115/21

Pharmacological Class:

Corticosteroid + long-acting beta-2 agonist (LABA).

Interactions:

Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, atazanavir, clarithromycin, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin): not recommended. Caution during or within 2 weeks of discontinuing MAOIs or tricyclic antidepressants, β-blockers (consider cardioselective), K+-depleting diuretics.

Adverse Reactions:

Upper respiratory tract infection or inflammation, throat irritation, dysphonia, headache, dizziness, nausea, vomiting; oral candidiasis, hypersensitivity reactions.

How Supplied:

Inhaler—12g (120 inh)